^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CCDC148 (Coiled-Coil Domain Containing 148)

    i
    Other names: CCDC148, Coiled-Coil Domain Containing 148, Coiled-Coil Domain-Containing Protein 148, MGC125588
    1year
    Urine exosomal lncRNAs as novel biomarkers for early diagnosis of bladder cancer based on microarray differential expression profiling. (PubMed, Int J Biol Markers)
    Tumor-originated urine exosomal lncRNAs, as fingerprint in NMIBC, exhibited satisfying clinical significance in early diagnosis of bladder cancer.
    Journal
    |
    CCDC148 (Coiled-Coil Domain Containing 148)
    2years
    Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms. (PubMed, Pharmacogenet Genomics)
    The study did not replicate previously reported associations with AIMSS risk for genetic variants in PPP1R14C and CCDC148 and AIMSS risk. Further research is needed to discover and validate genetic predictors of AIMSS that can be used to personalize treatment in patients with HR+ breast cancer.
    Journal
    |
    CCDC148 (Coiled-Coil Domain Containing 148)
    |
    HR positive
    over2years
    A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease. (PubMed, Zhejiang Da Xue Xue Bao Yi Xue Ban)
    Following corticosteroid treatment and discontinuation of alectinib, clinical presentations and CT scan gradually improved, but the primary lung lesions enlarged during the regular follow-up. The administration of crizotinib was then initiated and the disease was stable for 25 months without recurrence of primary lung lesions and ILD.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • CCDC148 (Coiled-Coil Domain Containing 148)
    |
    ALK rearrangement • EML4-ALK fusion • ALK fusion
    |
    Xalkori (crizotinib) • Alecensa (alectinib)